[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maxigen Biotech Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100609012","healiaid-collagen-wound-dressing-in-patients-undergoing-breast-tumor-surgery-100609012",false,"NCT07209020","HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery","Safety Observation of HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery: A Post-Market Clinical Trial","Inclusion Criteria:\n\n* Age 18-70 years old.\n* Patients are diagnosed with a benign or malignant breast tumor, that tumor size of ≦ 5 cm and no distant metastasis assessed by the imaging (breast ultrasonography, mammography, or MRI) and pathologic examination within 12 weeks before screening. If a benign breast tumor is identified through imaging and subsequently removed via surgery performed after the subject's enrollment in the study, the pathology report from that surgery should be used instead of any previous report.\n* Patients diagnosed with a breast tumor, or those with a history of radiation and chemotherapy, who are scheduled to undergo surgery such as partial mastectomy, breast-conserving surgery, sentinel lymph node dissection, and\u002For axillary lymph node dissection .\n* Patients who understand and are able to comply with follow-up visits and treatment during the trial period.\n* Patients who are willing and capable of providing written informed consent. Not a person subject to a sentence of guardianship or subject to judicial guardians.\n\nExclusion Criteria:\n\n* Patients with breast cancer stage III or IV.\n* Patients with inflammatory breast cancer.\n* Patients with multicentric lesions or lesions with diffuse microcalcification.\n* Patients with retro areolar breast carcinoma.\n* Have a history of severe allergies or are allergic to collagen.\n* Collagen vascular disease.\n* History of serious postoperative complications.\n* Infected wound.\n* Patients who require emergency surgery.\n* Patients with coagulation dysfunction, such as abnormal preoperative coagulation time (prothrombin time (PT)\\>18 seconds or partial thromboplastin time (PTT) \\>50 seconds)\n* Patients with untreated or unstable diabetes, that the fasting blood sugar \\>180 mg\u002FdL or postprandial blood sugar \\>200 mg\u002FdL.\n* Patients with untreated or unstable chronic diseases, such as hypertension, hyperlipidemia, cardiovascular disease, stroke.\n* Patients with Body mass index (BMI) \\> 30.\n* Patients who are pregnant or breastfeeding women.\n* Patients with drug abuse or addiction.\n* Others who have been judged by the principal investigator as participating in this trial will endanger their physical and mental health.","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the safety of the collagen wound dressing (HealiAid) in breast tumor patients with surgical treatment. The main questions it aims to answer are:\n\n1. To record the incidence of the postoperative complications and adverse events (AEs) after applying the HealiAid wound dressing in patients undergoing surgery for breast tumor.\n2. To evaluate the patients' satisfaction and quality of life using the Breast Q questionnaire before surgery and at weeks 2, 12, 26, and 52 after the surgery.\n3. To evaluate the patients' results of vital signs, hematology tests, tumor marker tests, breast ultrasonography, and mammography after the surgery.\n\nParticipants will undergo a breast surgery. Within the surgery procedure, the tumor will be completely removed with a margin of 1-2 cm surrounding healthy tissue and the wounds will be cleaned properly before the patients receive the HealiAid Collagen Wound Dressing at treatment visit, and six follow up visits at week 1, 2, 4, 12, 26 and 52.",[27,28,29],"Breast Tumors","Wound Healing","Collagen Wound Dressing",[31,32,33],"breast tumors","wound healing","collagen wound dressing","RECRUITING","2025-09-29",{"date":37,"type":38},"2025-10-06","ACTUAL",{"date":40,"type":38},"2025-05-20",{"date":42,"type":21},"2027-05-31",{"name":44,"class":45},"Maxigen Biotech Inc.","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100592524","artibest-for-knee-osteoarthritis-100592524","NCT06994546","ArtiBest for Knee Osteoarthritis","Intra Articular Hyaluronic Acid (ArtiBest ® ) for Knee Osteoarthritis: A Post-market, Open Label, Long Term Study","Inclusion Criteria:\n\n* Age from 35 to 85 years.\n* Subject with x ray imaging evidence of knee OA as Kellgren Lawrence grade = 2 or 3 within 1 month at screening.\n* Subject diagnosed with mild to moderate knee OA, particularly in patients who failed to respond adequately to conservative nonpharmacologic therapies or analgesics.\n* Subject with a 100 mm VAS resting pain score ≥ 30 mm in the studied knee at both the screening and treatment visit (screening visit and treatment visit can be on the same day)\n* Able and willing to comply with all study visits and procedures.\n* Willin g and capable of providing written informed consent.\n\nExclusion Criteria:\n\n* Subjects with known hypersensitivity to hyaluronate.\n* Subjects with infections or skin diseases in the area of the injection site.\n* Pregnancy or breast feeding woman.\n* Joining other interventional trial s within 3 months prior to injecting this study product\n* Subject receive an intra articular (IA) injection of Hyaluronic Acid (HA) and\u002For steroid in target knee within 6 months prior to the trial\n* Subjects with rheumatoid arthritis\n* Any surgery to the target knee within the 12 months prior to the trial, or surgery to the contralateral knee or other weight bearing joint if it will interfere with knee assessments","35 Years","85 Years",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate the real-world effectiveness and safety of ArtiBest in the treatment of knee osteoarthritis. The main questions it aims to answer are:\n\n1. The change from baseline The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 26 weeks post injection.\n2. The change from baseline VAS resting pain score at 12 and 26 weeks post injection.\n3. The change from baseline The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 12 weeks post injection.\n4. The change from baseline Patient's Global Assessment PGA) using VAS scoring at 12 and 26 weeks post injection.\n5. The OMERACT OARSI responder rate at 12 and 26 weeks post injection.\n6. The VAS satisfaction score at 12 and 26 weeks post injection\n7. The incidence of Adverse events reported during the study period.\n\nParticipants will undergo a single injection of ArtiBest at treatment visit, and three follow up visits at week 4 , 12 , and 26.",[59],"Knee Osteoarthristis",[61,62],"hyaluronic acid","intra articular injection",{"date":64,"type":38},"2025-05-29",{"date":66,"type":38},"2025-03-11",{"date":68,"type":21},"2026-04-30",{"name":44,"class":45},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":70},"100535523","effectiveness-and-safety-of-collagen-membrane-formaaid-in-the-treatment-of-periodontal-regeneration-100535523","NCT06252935","Effectiveness and Safety of Collagen Membrane (FormaAid®) in the Treatment of Periodontal Regeneration","A Single-Center, Evaluator-blind, Randomized Control Study to Assess the Effectiveness and Safety of Collagen Membrane (FormaAid®) in the Treatment of Periodontal Regeneration","Inclusion Criteria:\n\n* Age between 18 70 years old, male or female\n* Non current smoker: A person who has not smoked more than 100 cigarettes from the past to the present and has not smoked in the last 30 days.\n* Patients who have decided to pay at their own expense and require guided tissue regeneration (GTR) for periodontal regeneration\n* The defect morphology of intrabony defects is 2 or 3 wall intrabony defect.\n* Periodontal pocket depth ≥ 5mm (probing periodontal depth, PPD, distance from gingival margin to the bottom of the defect).\n* The height of the bone defect in the X ray image is ≥ 3mm (according to the X ray film intraosseous defect)\n* The diagnosis of periodontal disease is stage III with either grade B or C.\n* Patients who are willing to adhere to the study protocol and sign the informed consent form.\n* Willing to accept evaluation during the trial period and return to clinic and treatment.\n* Not a person subject to a sentence of guardianship or subject to judicial guardians.\n\nExclusion Criteria:\n\n* Have a history of severe allergies or be allergic to collagen.\n* Those who are known to be positive for human immunodeficiency virus.\n* Poorly controlled diabetes (untreated or unstable disease status), blood test measurement of glycated hemoglobin greater than 7%\n* Undergoing chemotherapy three months before agreeing to this experiment.\n* Patients undergoing meat product desensitization treatment.\n* Have a documented history of osteoporosis.\n* Chronic disease, hypertension, hyperlipidemia, cardiovascular disease, and stroke not properly controlled (untreated or unstable disease condition) judged by the investigator at screening.\n* Suffering from autoimmune diseases or connective tissue diseases, such as systemic lupus erythematosus or dermatomyositis.\n* Coagulation disorder, lab test prothrombin time (PT) \\> 12 sec , or the use of anticoagulants that affects surgery judged by the investigator at screening.\n* The tooth for which guided tissue regeneration (GTR) surgery is to be performed is determined to be furcation involved by investigator from image evaluation\n* The tooth for which guided tissue regeneration (GTR) surgery is to be performed is considered unhealthy, exhibiting conditions such as apical lesion, needed endodontic therapy tooth, tooth fracture, etc. etc., as judged by the investigator f rom image evaluation\n* Oral mucosal abnormalities or poor periodontal health, making it unsuitable for GTR surgical treatment, such as white spots, erythema, oral submucosal fibrosis, lichen planus, verrucous hyperplasia, inflammation, infection, etc. judged by the investigator at screening.\n* Those whose periodontal cleaning is not in good condition or who are unable to cooperate with periodontal cleaning. Plaque control index (O'Leary index) \\>15%\n* The mobility of the teeth that are to undergo guided tissue regeneration (GTR) surgery is greater than or equal to\n* Teeth that are to undergo guided tissue regeneration (GTR) surgery have incomplete adjacent teeth on both sides, such as dental prostheses, crowns or bridges, artificial dental implants, or metal fillings. materials, etc., so as to affect the image evaluation.\n* Others who are not suitable to participate in or continue this clinical trial as assessed by a physician.",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate clinically and radiographically effectiveness and products safety of the collagen membrane (FormaAid®) in the treatment of periodontal regeneration using guided tissue regeneration (GTR) performed by the trained periodontists. The main question it aims to answer are:\n\n* The difference of periodontal status: clinical attachment level (CAL), periodontal pocket depth (PPD), gingival recession (GR), gingival Index (GI) and plaque index (PI).\n* The difference of intrabony defect height.\n* The difference of gingival tissue thickness and gingival tissue volume.\n* The incidences of safety indicators.\n\nParticipants will be randomized into either experiment group or control group, undergo guided tissue regeneration (GTR) surgery at week 1, and re-visited on week 3, 5, 13 and 27 after the GTR surgery.\n\nResearchers will compare if the test product is non-inferior to Bio-Gide.",[82,83,84],"Guided Tissue Regeneration","Collagen Membrane","Dental Diseases","2025-05-06",{"date":87,"type":38},"2025-05-09",{"date":89,"type":38},"2024-07-30",{"date":91,"type":21},"2025-10-31",{"name":44,"class":45},""]